COVID-19: Case fatality and ACE2 inhibitors treatment concerns in patients with comorbidities
- PMID: 33437743
- PMCID: PMC7787016
- DOI: 10.34171/mjiri.34.147
COVID-19: Case fatality and ACE2 inhibitors treatment concerns in patients with comorbidities
Abstract
The Corona Virus Disease 2019 (COVID-19) outbreak is becoming pandemic with the highest mortality in patients with associated comorbidities. These RNA viruses containing 4 structural proteins usually use spike protein to enter the host cell. Angiotensin-converting enzyme 2 (ACE2) acts as a host receptor for the virus. Therefore, medications acting on renin-angiotensin-aldosterone system can lead to serious complications, especially in patients with diabetes and hypertension. To avoid this, other potential treatment modalities should be used in COVID-19 patients with associated comorbidities.
Keywords: ACE2 inhibitors; Associated comorbidities; COVID-19; Treatment; Type 2 diabetes.
© 2020 Iran University of Medical Sciences.
Conflict of interest statement
Conflicts of Interest: None declared
References
Publication types
LinkOut - more resources
Full Text Sources